Millennium Management
SLN

Millennium Management’s Silence Therapeutics SLN Stock Holding History

Millennium Management’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.66M Buy
1,074,191
+414,599
+63% +$2.28M ﹤0.01% 2795
2025
Q4 		$4.01M Buy
659,592
+361,080
+121% +$2.31M ﹤0.01% 3258
2025
Q3 		$1.55M Buy
298,512
+99,865
+50% +$555K ﹤0.01% 4272
2025
Q2 		$1.15M Sell
198,647
-198,215
-50% -$850K ﹤0.01% 4299
2025
Q1 		$1.12M Sell
396,862
-76,690
-16% -$374K ﹤0.01% 4268
2024
Q4 		$3.26M Sell
473,552
-636,678
-57% -$8.22M ﹤0.01% 3221
2024
Q3 		$20.2M Buy
1,110,230
+327,289
+42% +$6.09M 0.01% 1544
2024
Q2 		$14.9M Buy
782,941
+373,523
+91% +$7.94M 0.01% 1746
2024
Q1 		$8.84M Buy
+409,418
New +$8.9M ﹤0.01% 2303
2023
Q3 		– Sell
-22,832
Closed -$126K – 6519
2023
Q2 		$126K Buy
22,832
+3,148
+16% +$19K ﹤0.01% 5272
2023
Q1 		$122K Buy
19,684
+2,248
+13% +$26.5K ﹤0.01% 5351
2022
Q4 		$266K Buy
17,436
+2,879
+20% +$37.7K ﹤0.01% 5171
2022
Q3 		$144K Buy
+14,557
New +$153K ﹤0.01% 5828

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Millennium Management's SLN Position: Q1 2026 in Review

Millennium Management increased its Silence Therapeutics (SLN) stake by 63% in Q1 2026, buying an estimated $2.28M and bringing the position to 1,074,191 shares worth $5.66M. The position accounts for ﹤0.01% of the portfolio, ranked #2795.

Millennium Management first reported a position in SLN in Q3 2022 and has held it in 13 quarters since. The position peaked at $20.2M in Q3 2024. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • Millennium Management held 1,074,191 shares of Silence Therapeutics worth $5.66M as of Q1 2026.
  • Millennium Management bought 414,599 Silence Therapeutics shares in Q1 2026, an estimated $2.28M.
  • Silence Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2795 holding.
  • Millennium Management first reported a position in Silence Therapeutics in Q3 2022 and has held it in 13 quarters since.
  • Millennium Management's Silence Therapeutics position peaked at $20.2M in Q3 2024.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.